Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sensitivity analysis of EGFR L861Q mutation to six tyrosine kinase inhibitors.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico - 1 Oct 2022

Liu Chang, Wang Zhenxing, Liu Qian, Wu Guangyao, Chu Chunhong, Li Lanxin, An Lei, Duan Shaofeng

Abstract excerpt

PURPOSE: Lung cancer is one of the most common carcinomas with the highest mortality in the world. Non-small cell lung carcinoma has a large proportion of epidermal growth factor receptor (EGFR) mutations, of which rare EGFR mutations account for about 10%-20%. Currently, tyrosine kinase inhibitors (TKIs) therapy is a standard treatment for patients with non-small cell lung carcinoma with EGFR mutations. To date,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Erlotinib Hydrochloride

Share to Gefitinib

Share to Lung Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 35666454
DOI: 10.1007/s12094-022-02854-3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sensitivity analysis of EGFR L861Q mutation to six tyrosine kinase inhibitors.PMID 35666454Read ↗

Six first-line tyrosine kinase inhibitors reveal novel inhibition potential for the EGFR S768I mutation.Semantic proximity Read ↗

Iterative Upgrading of Small Molecular Tyrosine Kinase Inhibitors for EGFR Mutation in NSCLC: Necessity and PerspectiveSemantic proximity Read ↗

A novel role for WZ3146 in the inhibition of cell proliferation via ERK and AKT pathway in the rare EGFR G719X mutant cells.Semantic proximity Read ↗

Defining the Sensitivity Landscape of 74,389 EGFR Variants to Tyrosine Kinase InhibitorsSemantic proximity Read ↗

Defining the Sensitivity Landscape of 74,389 EGFR Variants to Tyrosine Kinase InhibitorsSemantic proximity Read ↗

Potential CRISPR/Cas9 Gene Editing Applications in Reversing Acquired Resistance to EGFR-TKIs due to Secondary and Tertiary Mutations to EGFR in NSCLCSemantic proximity Read ↗

CRISPR-mediated modulation of EGFR signaling in lung cancer.Semantic proximity Read ↗

Determining EGFR-TKI sensitivity of G719X and other uncommon EGFR mutations in non-small cell lung cancer: Perplexity and solution (Review).Semantic proximity Read ↗

BDTX-189, a novel tyrosine kinase inhibitor, inhibits cell activity via ERK and AKT pathways in the EGFR C797S triple mutant cells.Semantic proximity Read ↗

Almonertinib and alflutinib show novel inhibition on rare EGFR S768I mutant cells.Semantic proximity Read ↗

Defining the sensitivity landscape of EGFR variants to tyrosine kinase inhibitors.Semantic proximity Read ↗

Generation of lung cancer cell lines harboring EGFR T790M mutation by CRISPR/Cas9-mediated genome editing.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.